Destiny Pharma
      
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • Our Values
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News and Media
    • Media
    • Events
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Careers
  • Contact
27 May 2022 – Result of Annual General Meeting and Strategy Update
26 May 2022 – Destiny Pharma plc Board changes
12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe
04 May 2022 – Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about her role
03 May 2022 – Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer
27 April 2022 – Posting of Annual Report and Notice of AGM

News

Latest News

  • 27 May 2022 – Result of Annual General Meeting and Strategy Update
  • 26 May 2022 – Destiny Pharma plc Board changes
  • 12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe
  • 04 May 2022 – Destiny’s Chief Business Officer, Dr Stephanie Bewick, speaks to Labiotech about her role
  • 03 May 2022 – Destiny Pharma appoints Dr Yuri Martina as Chief Medical Officer
  • 27 April 2022 – Posting of Annual Report and Notice of AGM
  • 12 April 2022 – Audited results for year ended 31 December 2021
  • 31 March 2022 – Presenting data at the ECCMID 2022 Congress
  • 28 March 2022 – Result of General Meeting and Total Voting Rights
  • 25 March 2022 – Result of Open Offer
  • 25 March 2022 – Destiny’s microbiome project article published in Vantage
  • 23 March 2022 – Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Rise in AMR Threatens Infection Armageddon”
  • 22 March 2022 – Exercise of Options and Total Voting Rights
  • 17 March 2022 – Open Offer Application Form
  • 17 March 2022 – Form of Proxy
  • 09 March 2022 – Circular to shareholders
  • 08 March 2022 – Fundraising
  • 08 February 2022 – Positive feedback from EMA on XF-73 Nasal gel Phase 3 programme
  • 01 February 2022 – Positive data in XF-73 Dermal study with NIAID
  • 24 January 2022 – Clinical and commercial opportunity of NTCD-M3
  • 21 January 2022 – Destiny Pharma Lancet Report
  • 17 January 2022 – Strategy/Company/Ops Update

Archive

2021

2020 & Prior

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement